Aquestive CPO has 56,778 shares withheld for taxes

Aquestive Therapeutics Chief People Officer Peter E. Boyd reported a tax-related share disposition tied to equity compensation.

Rhea-AI Filing Summary

Aquestive Therapeutics Chief People Officer Peter E. Boyd reported a tax-related share disposition tied to equity compensation. On the vesting of previously granted Performance Stock Units, 56,778 shares of common stock were withheld by Aquestive to cover his tax withholding obligation at $4.18 per share.

After this tax withholding event, Boyd directly holds 281,731 shares of Aquestive Therapeutics common stock. The transaction was coded as a tax-withholding disposition (code F), indicating an administrative settlement of taxes rather than an open-market trade.

Insider Trade Summary

Exercise Price or Tax Liability: 56,778 shares

Exercise Price or Tax Liability 1 txn

Insider Boyd Peter E.

Role Chief People Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	56,778	$4.18	$237K

Holdings After Transaction: Common Stock — 281,731 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Key Figures

Shares withheld for taxes: 56,778 shares Withholding price per share: $4.18 per share Shares held after transaction: 281,731 shares

3 metrics

Shares withheld for taxes 56,778 shares Tax withholding on PSU vesting, code F

Withholding price per share $4.18 per share Value used for tax-withholding disposition

Shares held after transaction 281,731 shares Direct common stock ownership after withholding

Key Terms

Performance Stock Units ("PSUs"), tax withholding obligation, vesting, Form 4

4 terms

Performance Stock Units ("PSUs") financial

"in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted"

tax withholding obligation financial

"shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation"

vesting financial

"in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aquestive Therapeutics (AQST) report for Peter E. Boyd?

Aquestive Therapeutics reported that Chief People Officer Peter E. Boyd had 56,778 common shares withheld to satisfy tax obligations. The withholding occurred upon vesting of previously granted Performance Stock Units and was recorded as a Form 4 tax-withholding disposition, not an open-market trade.

How many Aquestive (AQST) shares were withheld for Peter Boyd’s taxes and at what price?

A total of 56,778 Aquestive Therapeutics common shares were withheld to cover Peter Boyd’s tax withholding obligation. The withholding price was $4.18 per share, reflecting the value used to settle the tax liability associated with vesting Performance Stock Units previously granted to him.

How many Aquestive (AQST) shares does Peter E. Boyd hold after this Form 4 event?

Following the tax-withholding disposition, Peter E. Boyd directly holds 281,731 shares of Aquestive Therapeutics common stock. This figure reflects his remaining direct ownership after 56,778 shares were withheld by the issuer to satisfy his tax obligations from vesting Performance Stock Units.

What does transaction code F mean in the Aquestive (AQST) Form 4 for Peter Boyd?

Transaction code F on Peter Boyd’s Form 4 indicates shares were disposed of to pay taxes or exercise costs. In this case, 56,778 shares were withheld by Aquestive Therapeutics to satisfy his tax withholding obligation related to the vesting of Performance Stock Units, not sold on the market.

Were Peter Boyd’s Aquestive (AQST) shares sold on the open market in this filing?

No, the Form 4 shows shares were withheld by Aquestive Therapeutics for taxes rather than sold on the open market. The 56,778 shares were used to satisfy Peter Boyd’s tax withholding obligation tied to the vesting of Performance Stock Units previously granted to him.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 05:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boyd Peter E.

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		F		56,778(1)	D	$4.18	281,731	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)